ArticleJournal of arrhythmia2025
Trends in atrial fibrillation and flutter mortality associated with disorders of thyroid gland in the United States from 1999 to 2020.
Article in Journal of arrhythmia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Trends in atrial fibrillation and flutter mortality associated with disorders of thyroid gland in the United States from 1999 to 2020.Journal of arrhythmia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid gland disorders are a known risk factor for atrial fibrillation and flutter (AF/AFL). Despite being a well-established risk factor, most studies have primarily examined prevalence, comorbidities, and treatment patterns with little to no research on mortality trends for this association. Objective: We aimed to analyze the trends in AF/AFL-related mortality in patients with thyroid gland disorders. Methods: Age-adjusted mortality rates and crude rates per 100,000 population from 1999 to 2020 using the CDC WONDER database. Annual percent changes and their averages were calculated via Joinpoint regression. AF/AFL-related mortality trends in patients with thyroid disorders were compared with those in the general population using pairwise comparison. Results: In the study period, a total of 7187 AF/AFL-related deaths were observed in individuals diagnosed with thyroid gland disorders. The age-adjusted mortality rates increased throughout the study period. The mortality rates in females remained consistently higher than those in males. Mortality rates did not vary substantially across regions (South: 0.09; Northeast: 0.09; Midwest: 0.10; West: 0.11). Furthermore, the annual percent change in females and South with thyroid disorders differed significantly from the general population. The states with the highest mortality rates were Oregon, Wyoming, and Nebraska. The mortality rates remained higher in nonmetropolitan regions (0.11) than in metropolitan regions (0.09). Conclusions: AF/AFL-related mortality trends associated with thyroid disorders increased from 1999 to 2020. Policies that target vulnerable populations and regions may be beneficial in mitigating the increasing AF/AFL-related mortality associated with disorders of the thyroid gland.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.